Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MULTIPLE MYELOMA (MM)”

419 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 419 results

Not applicableStudy completedNCT01472627
What this trial is testing

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

Who this might be right for
Multiple Myeloma
Dana-Farber Cancer Institute 11
Early research (Phase 1)Ended earlyNCT02931110
What this trial is testing

Study of IV CBL0137 in Previously Treated Hematological Subjects

Who this might be right for
Hematological Malignancies
Incuron 5
Testing effectiveness (Phase 2)Ended earlyNCT02431260
What this trial is testing

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Who this might be right for
Solid Tumors and Hematologic Malignancy
Incyte Corporation 69
Not applicableNot Yet RecruitingNCT07646873
What this trial is testing

PET-Enabled Dual-Energy CT in Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
University of California, Davis 45
Not applicableEnrolling By InvitationNCT06472830
What this trial is testing

MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study

Who this might be right for
Monoclonal Gammopathy of Undetermined Significance
Mayo Clinic 1,000
Large-scale testing (Phase 3)Active Not RecruitingNCT04071457
What this trial is testing

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Who this might be right for
Multiple Myeloma
SWOG Cancer Research Network 1,100
Testing effectiveness (Phase 2)Looking for participantsNCT06627751
What this trial is testing

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Who this might be right for
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 28
Early research (Phase 1)Study completedNCT03263637
What this trial is testing

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Who this might be right for
Relapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+8 more
AstraZeneca 44
Testing effectiveness (Phase 2)WithdrawnNCT03608501
What this trial is testing

Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

Who this might be right for
Multiple Myeloma
Takeda
Testing effectiveness (Phase 2)UnknownNCT00800059
What this trial is testing

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Who this might be right for
Multiple Myeloma
Ottawa Hospital Research Institute 27
Testing effectiveness (Phase 2)UnknownNCT00378755
What this trial is testing

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Who this might be right for
Multiple Myeloma
Korean Multiple Myeloma Working Party 62
Post-approval studies (Phase 4)Study completedNCT06425276
What this trial is testing

Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation

Who this might be right for
Multiple Myeloma
CASI Pharmaceuticals (China) Co., Ltd. 67
Post-approval studies (Phase 4)Ended earlyNCT02773550
What this trial is testing

Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Basque Health Service 24
Testing effectiveness (Phase 2)Looking for participantsNCT05294055
What this trial is testing

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Who this might be right for
Multiple MyelomaLymphoma
Institute of Hematology & Blood Diseases Hospital, China 120
Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Testing effectiveness (Phase 2)UnknownNCT03940833
What this trial is testing

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Who this might be right for
Multiple Myeloma
Asclepius Technology Company Group (Suzhou) Co., Ltd. 20
Not applicableNot Yet RecruitingNCT07376733
What this trial is testing

Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Breathing TechniquesBreathing Exercises+3 more
Universidad Complutense de Madrid 26
Not applicableLooking for participantsNCT06515262
What this trial is testing

Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 10
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Next Page